Gastroenterology

Back to articles

Alosetron: Banned Medication Coming Back?

KEY POINT

Alosetron (Lotronex—GlaxoSmithKine [GSK]), withdrawn in November 2000 after only 9 months on the U.S. market, appears likely to be resurrected later this year, albeit with restrictions. If FDA staff members heed the advice of two advisory panels, the serotonin (5-HT3) antagonist would be indicated for treating women with diarrhea-predominant irritable bowel syndrome (IBS) who have failed conventional therapy.